Skip to main content

Published locations for Oral idelalisib elicits response in half of refractory CLL patients

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Oral idelalisib elicits response in half of refractory CLL patients

User login

  • Reset your password
  • /content/oral-idelalisib-elicits-response-half-refractory-cll-patients
  • /internalmedicinenews/article/58821/oncology/oral-idelalisib-elicits-response-half-refractory-cll
  • /oncologypractice/article/58821/oncology/oral-idelalisib-elicits-response-half-refractory-cll
  • /hematology-oncology/article/58821/oncology/oral-idelalisib-elicits-response-half-refractory-cll
  • /internalmedicine/article/58821/oncology/oral-idelalisib-elicits-response-half-refractory-cll